Fig. 1

Acetyl-Prx1 is decreased in AD patients’ brains, and Aβ and HDAC6 inhibitor modulate Prx1 acetylation. a Representative images of acetyl-Prx1 level in human brain samples. Top row shows representative images of age- and sex-matched normal control brains and bottom row shows AD brains. Scale bar: 100 μm. b Acetylation level of Prx1 in primary hippocampal neurons. Primary hippocampal neurons were treated with Aβ (2 μM, 24 h) and then co-treated with TBA (1 μM, 3 h). Endogenous Prx1 was immunoprecipitated by anti-Prx1 antibody which was cross-linked to protein A/G coated agarose beads and probed by indicated antibodies. Left panel shows immunoblot images and right panel shows quantification of acetylation level of Prx1 which normalized by immunoprecipitated total Prx1 (n = 4, independent experiments). c Acetylation level of Prx1 in HT22 cells. Prx1-WT-Flag transfected HT22 cells were treated with Aβ (2 μM, 24 h) and then co-treated with TBA (0.5 μM, 3 h). Prx1-Flag was immunoprecipitated by anti-Flag M2 magnetic beads and probed by indicated antibodies. Left panel shows immunoblot images and right panel shows quantification of acetylation level of Prx1 which normalized by immunoprecipitated total Prx1 (n = 4, independent experiments). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (two-way ANOVA, Bonferroni post-hoc test)